A PCP's Guide to Dyslipidemia

Slides:



Advertisements
Similar presentations
The Latest Lipid Guidelines:
Advertisements

Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Cholesteryl Ester Transfer Protein Inhibitors
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
American Heart Association Scientific Sessions
Obesity and Dyslipidemia: How Would You Treat?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
What Do We Know About LDL-C?
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
Blood pressure control: dependence on adherence
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Assessing the State of Statin Therapy
An Update on PCSK9 Inhibitors
A Pharmacist's Guide to PCSK9 Inhibitors:
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
62-year-old Man With Unstable Angina
Personalizing Statin Therapy in Patients With HIV
PCSK9 Inhibitors and Cardiovascular Outcomes
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Statins and HIV:.
New LDL-C Lipid Targets
Radical New Concepts in Lipid Management
Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia
Lipid Clinic Challenge
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
Glucose Management and Statin Therapy
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Latest Lipid Guidelines in Perspective
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Reducing Risk for CV Outcomes
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Glucose Management and Statin Therapy
PCSK9 Inhibitors and Statin Intolerance
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Presentation transcript:

A PCP's Guide to Dyslipidemia

Current Recommendations ACC/AHA Cholesterol Guidelines/Risk stratification

Risk Calculators

New Options The PCSK9 Variant Story

Patient Follow-Up

PCSK9 Inhibitors 2 Key Indications

PCSK9 Inhibitors Effects on LDL-C and CV Events

Does Reduction in LDL Cholesterol Equal Less Cardiovascular Events Does Reduction in LDL Cholesterol Equal Less Cardiovascular Events? IMPROVE-IT

Case Discussion Understanding FH

Case: Patient Failed to Attain Lipid Goal on Statin Monotherapy

Pharmacoeconomic Issues

Primary Care Management

Patient/Drug Selection and Insurance Coverage

Consider Cost and Precertification for Highest Risk Patients

Summary

Abbreviations

Abbreviations (cont)